Caspofungin Acetate Injection shortage
To Be Discontinued 3 presentations · 2 manufacturers · first FDA posting Jan 12, 2026 · last update Jun 30, 2026
Manufacturers: Fresenius Kabi USA, LLC, Jiangsu Hengrui Pharmaceuticals Co. (US Agent eVenus Pharmaceutical Laboratories, Inc.)
Stated reasons (per FDA): Not stated
More info: FDA Drug Shortages Database · ASHP drug shortages list (search there for this drug)
Presentations
| Presentation | Manufacturer | Status | Reason | Notes (FDA) | Dates |
|---|---|---|---|---|---|
| Caspofungin Acetate, Injection, 7 mg/1 mL (NDC 63323-358-10) | Fresenius Kabi USA, LLC | To Be Discontinued | — | Discontinuation of the manufacture of the drug | Posted Jan 12, 2026 Updated Jan 12, 2026 Discontinued Jan 12, 2026 |
| Caspofungin Acetate, Injection, 5 mg/1 mL (NDC 0781-3421-94) | Jiangsu Hengrui Pharmaceuticals Co. (US Agent eVenus Pharmaceutical Laboratories, Inc.) | To Be Discontinued | — | Marketed by Sandoz, Inc.; Discontinuation of the manufacture of the drug | Posted Jun 30, 2026 Updated Jun 30, 2026 Discontinued Jun 30, 2026 |
| Caspofungin Acetate, Injection, 7 mg/1 mL (NDC 0781-3423-94) | Jiangsu Hengrui Pharmaceuticals Co. (US Agent eVenus Pharmaceutical Laboratories, Inc.) | To Be Discontinued | — | Marketed by Sandoz, Inc.; Discontinuation of the manufacture of the drug | Posted Jun 30, 2026 Updated Jun 30, 2026 Discontinued Jun 30, 2026 |